Johnson & Johnson has reached a voluntary agreement with the Trump administration to improve access to medicines and reduce costs for American patients. This agreement also exempts the company’s pharmaceutical products from tariffs.
Joaquin Duato, chairman and CEO of Johnson & Johnson, stated, “Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy. I’m proud that Johnson & Johnson is answering President Trump’s call to lower drug prices for everyday Americans while maintaining our role in improving and saving lives and ensuring that the United States continues to lead the world in healthcare innovation.”
The company confirmed it is continuing with its previously announced $55 billion investment aimed at strengthening U.S. manufacturing, research and development, as well as technology by early 2029. Over the past 10 months, billions have already been invested in U.S. manufacturing operations as part of a plan to produce most of its advanced medicines domestically.
As part of this investment initiative, Johnson & Johnson announced two new manufacturing facilities in the United States: a next-generation cell therapy site in Pennsylvania and a modern drug product facility in North Carolina.
Construction is underway on a $2 billion biologics manufacturing facility in Wilson, North Carolina—a project expected to create about 5,000 skilled jobs for both manufacturing and construction roles. The company has begun hiring advanced manufacturing staff for this location.
Additionally, last September saw Johnson & Johnson secure a new biopharmaceutical manufacturing site spanning over 160,000 square feet in Holly Springs, North Carolina. This ten-year commitment involves an additional $2 billion investment and will generate around 120 new jobs in the state.
